Whistleblower program compliance

Whistleblower program compliance in Healthcare & Life Sciences sits at the intersection of two overlapping enforcement regimes: the U.S. Department of Health and Human Services Office of Inspector General's voluntary disclosure protocols and the U.S. Securities and Exchange Commission's whistleblower award program under Dodd-Frank Section 922, which applies to publicly traded health systems, biopharma, and medtech companies alike. The False Claims Act's qui tam provisions add a third layer, giving relators independent standing to file even when internal compliance programs exist. Compliance teams at life sciences companies are currently auditing whether their internal reporting channels meet the anti-retaliation safe harbor standards that OIG and SEC examiners have flagged in recent enforcement patterns.